S&P edges closer to record high; energy shares lead

Go back to S&P edges closer to record high; energy shares lead

Opicinumab Phase 2 Miss No Surprise; Leerink Affirms Biogen (BIIB) at 'Market Perform'

June 7, 2016 11:54 AM EDT

Leerink affirms Biogen (Nasdaq: BIIB) with a Market Perform rating and $319 price target after the company announced that its Phase 2 SYNERGY study of opicinumab... More